Aethlon Medical, Inc. (OTCQB: AEMD) creates affinity biofiltration devices to treat life-threatening diseases. The company’s leading therapeutic candidate, the Aethlon Hemopurifier®, is a broad-spectrum therapeutic strategy developed to address drug resistant viral pathogens. To date, the device, which was recently named among ‘The 11 Most Remarkable Advances in Healthcare’ by Time Magazine, has been successfully administered to individuals infected with Ebola virus, hepatitis C and the human immunodeficiency virus (HIV), demonstrating the immense potential for the company’s novel treatment device moving forward.
In addition to validating the treatment of some of the world’s deadliest pathogens, Aethlon is also investigating the use of its Hemopurifier therapy to capture tumor-derived exosomes, which have been shown to promote cancer progression. When complete, this application will address a substantial demand within the cancer treatment market. In April, the company took a significant step toward the eventual commercialization of its proprietary therapeutic candidate by entering into a clinical trial agreement with the University of California, Irvine to establish baseline exosome levels and monitor their associations with various types of cancers. The results of this study will help direct future clinical investigations.
The company’s current product pipeline is built upon its revolutionary Aethlon ADAPT™ system, which is an adaptive dialysis-like affinity platform technology that provides the foundation for a new class of therapeutics that target the selective clearance of harmful agents from the circulatory system. In addition to the Hemopurifier, Aethlon is currently utilizing this system to develop HER2osome™ to target HER2+ breast cancer and a novel medical device to reduce the incidence of sepsis in combat-injured soldiers, which is sponsored by the Defense Advanced Research Projects Agency (DARPA).
Exosome Sciences, Inc., Aethlon’s majority-owned subsidiary, is supporting this product development through the creation of its groundbreaking diagnostic tool, ELLSA™. This device provides greater exosome detection sensitivity than any other product currently on the marketplace. With ELLSA, Aethlon gains enhanced ability to identify and quantify the underlying presence of exosomes in a wide variety of relevant treatment applications.
As Aethlon continues to develop its unique pipeline of therapeutic solutions, the potential for market growth upon commercialization is effectively limitless. With a potential uplisting to the NASDAQ Capital Markets currently pending approval, it is an exciting time for shareholders of this company.
For more information, visit www.aethlonmedical.com
